[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338340-105":59,"doc-detail-338340-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mediators-of-racial-and-ethnic-inequities-in-clinical-trial-participation-among-patients-with-cancer-article-summary","Mediators of racial and ethnic inequities in clinical trial participation among patients with cancer - Article - Summary","","Background: Although racially and ethnically minoritized populations are less likely to participate in cancer trials, the role of social determinants of health (SDOH) in explaining these gaps is unclear. Methods: This retrospective cohort study used electronic health record data (2011–2023) linked to neighborhood (US Census tract) data, with follow-up to clinical study drug receipt as a proxy for participation. Mediation analysis quantified which area-level SDOH explained trial inequities. Results: Black and Latinx patients participated less than White patients; mediators accounted for 62.2% of Black-White inequities and 65.1% of Latinx-White inequities. Conclusions: Addressing barriers tied to adverse neighborhood SDOH is necessary to improve cancer trial diversity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mediators-of-racial-and-ethnic-inequities-in-clinical-trial-participation-among-patients-with-cancer-article-summary/338340/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mediators-of-racial-and-ethnic-inequities-in-clinical-trial-participation-among-patients-with-cancer-article-summary/338340.png","ImageObject",300,407,{"name":92,"@type":93},"Sage","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study trying to determine about trial participation inequities?","Question",{"text":112,"@type":113},"The study examined whether social determinants of health (SDOH) explain racial and ethnic inequities in clinical trial participation among patients with cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the researchers measure clinical trial participation?",{"text":117,"@type":113},"Patients were followed from diagnosis to clinical study drug receipt, treated as a proxy for trial participation, along with death or last recorded activity.",{"name":119,"@type":110,"acceptedAnswer":120},"Which factors mediated the inequities between Black/Latinx and White patients?",{"text":121,"@type":113},"Area-level SDOH—including segregation and vehicle ownership—were key mediators for Black-White inequities, and segregation, limited English proficiency, and vehicle ownership were important for Latinx-White inequities.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338340,1790713851,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","JNCI Cancer Spectrum, 2024, 8(5), pkae085  \n[https://doi.org/10.1093/jncics/pkae085](https://doi.org/10.1093/jncics/pkae085)  \nAdvance Access Publication Date: September 13, 2024  \nArticle  \nMediators of racial and ethnic inequities in clinical trial participation among patients with cancer, 2011-2023  \nJenny S. Guadamuz , MSPH, PhD,1,2,􀀃 Xiaoliang Wang , MPH, PhD,1 Ivy Altomare , MD,1 Wendy Camelo Castillo , MD, MSc, PhD,3 Somnath Sarkar, PhD,1 Ronac Mamtani , MD, MSCE,4 Gregory S. Calip , PharmD, MPH, PhD1,5,6  \n1Flatiron Health, New York, NY, USA  \n2Division of Health Policy and Management, School of Public Health, University of California, Berkeley, Berkeley, CA, USA 3Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, MD, USA 4Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA  \n5Now with AbbVie, North Chicago, IL, USA  \n6Program on Medicines and Public Health, Alfred E. Mann School of Pharmacy, University of Southern California, Los Angeles, CA, USA  \n􀀃 Correspondence to: Jenny S. Guadamuz, PhD, Division of Health Policy and Management, University of California, Berkeley, School of Public Health, 2121 Berkeley Way, Berkeley, CA 94720, USA ([e-mail: jennyguadamuz@berkeley.edu](e-mail: jennyguadamuz@berkeley.edu)) .  \nAbstract  \nBackground: Although racially and ethnically minoritized populations are less likely to participate in cancer trials, it is unknown whether social determinants of health (SDOH) explain these inequities. Here we identify SDOH factors that contribute to racial and ethnic inequities in clinical trial participation among patients with 22 common cancers.  \nMethods: This retrospective cohort study used electronic health record data (2011-2023) linked to neighborhood (US Census tract) data from multiple sources. Patients were followed from diagnosis to clinical study drug receipt (proxy for trial participation), death, or last recorded activity. Associations were assessed using Cox proportional hazards models adjusted for clinical factors (year of diagnosis, age, sex, performance status, disease stage, cancer type) . To elucidate which area-level SDOH underlie racial and ethnic inequities, mediation analysis was performed using nonlinear multiple additive regression tree models.  \nResults: This study included 250 105 patients (64.7% non-Latinx White, 8.9% non-Latinx Black, 5.2% Latinx) . Black and Latinx patients were more likely to live in economically or socially marginalized areas (eg, disproportionately minoritized [measure of segregation], limited English proficiency, low vehicle ownership) than White patients. Black (3.7%; hazard ratio ¼ 0.55, 95% confidence interval [CI] ¼ 0.52 to 0.60) and Latinx patients (4.4%; hazard ratio ¼ 0.63, 95% CI ¼ 0.58 to 0.69) were less likely to participate in trials than White patients (6.3%) . Fewer patients in economically or socially marginalized neighborhoods participated in trials. Mediators explained 62.2%(95% CI ¼ 49.5% to 74.8%) of participation inequities between Black and White patients; area-level SDOH—including segregation (29.9%, 95% CI ¼ 21.2% to 38.6%) and vehicle ownership (11.6%, 95% CI ¼ 7.0% to 16.1%)—were the most important mediators. Similarly, Latinx-White participation inequities were mediated (65.1%, 95% CI ¼ 49.8% to 80.3%) by area-level SDOH, such as segregation (39.8%, 95% CI ¼ 28.3% to 51.3%), limited English proficiency (11.6%, 95% CI ¼ 2.8% to 20.4%), and vehicle ownership (9.6%, 95% CI ¼ 5.8% to 13.5%) .  \nConclusions: To improve racial and ethnic diversity in cancer trials, efforts to address barriers related to adverse neighborhood SDOH factors are necessary.  \nIn the United States, less than 5% of patients with cancer participate in clinical trials, and racially and ethnically minoritized populations, especially Black and Latinx patients, are less likely to participate (1-3) . These persistent racial and ethni","cbCaifogX7jv14CB","https://ap.wps.com/l/cbCaifogX7jv14CB","pdf",1218209,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions","[{\"question\":\"What was the study trying to determine about trial participation inequities?\",\"answer\":\"The study examined whether social determinants of health (SDOH) explain racial and ethnic inequities in clinical trial participation among patients with cancer.\"},{\"question\":\"How did the researchers measure clinical trial participation?\",\"answer\":\"Patients were followed from diagnosis to clinical study drug receipt, treated as a proxy for trial participation, along with death or last recorded activity.\"},{\"question\":\"Which factors mediated the inequities between Black/Latinx and White patients?\",\"answer\":\"Area-level SDOH—including segregation and vehicle ownership—were key mediators for Black-White inequities, and segregation, limited English proficiency, and vehicle ownership were important for Latinx-White inequities.\"}]","Mediators of racial and ethnic inequities in clinical trial participation among patients with cancer - Article - Summary | PDF",1790023135,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f32a3e5f44e706796a017af7b6414d80.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dc18e676b3946cf266227e2cc111cd91.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8a4598575b933dd631d88e5996030465.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cb72dce51d759d2cdaec03c91f48c4b5.webp",980,1287]